Assessment of the involvement of CYP3A in the vitro metabolism of a new modulator of MDR in cancer chemotherapy, OC144-193, by human liver microsomes

European Journal of Drug Metabolism and Pharmacokinetics

Volumn 26, Issue 4, 2001, Pages 273-282

  Guns, Emma S ^a,b   Bullock, Peter L ^c   Reimer, Mark L J ^c   Marcel Bally, Ross Dixon ^a,d   Mayer, Lawrence D ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c MDS Inc   (Canada)

^d Ontogen Corporation   (Canada)

Author keywords

Chemotherapy; Cytochrome P450; Human liver microsomes; MDR modulator; OC144 093

Indexed keywords

CARBON MONOXIDE; CYTOCHROME P450 2B6; CYTOCHROME P450 2C9; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; DIETHYLDITHIOCARBAMIC ACID; ENZYME INHIBITOR; FURAPHYLLINE; IMIDAZOLE DERIVATIVE; KETOCONAZOLE; MEPHENYTOIN; OC 144 092; OC 144 093; QUINIDINE; SULFAPHENAZOLE; TOLBUTAMIDE; TROLEANDOMYCIN; UNCLASSIFIED DRUG; VINYLIDENE CHLORIDE;

ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; LIVER MICROSOME; MICHAELIS CONSTANT; MULTIDRUG RESISTANCE; PHARMACOKINETICS;

ARYL HYDROCARBON HYDROXYLASES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG RESISTANCE, MULTIPLE; HUMANS; IMIDAZOLES; MICROSOMES, LIVER; MODELS, CHEMICAL; OXIDOREDUCTASES, N-DEMETHYLATING; P-GLYCOPROTEIN;

EID: 0035686183     PISSN: 03787966     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03226382     Document Type: Article

References (35)

1. Discovery and characterization of OC a novel inhibitor of Pgp mediated MDR
2. P-glycoproteins and multidrug resistance
3. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy
4. Potentiation of anticancer drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane potential
5. A, reversal of multidrug resistance by verapamil analogues
6. The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and -sensitive leukemia in vitro and in vivo
7. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
8. SDZ PSC833, a non-immunosuppressive cyclosporin: Its potency in overcoming P-glycoprotein mediated multidrug resistance of murine leukemia
9. Phase I pharmacokinetic study of Cyclosporin A combined with Doxorubicin
10. The effect of verapamil on the pharmacokinetics of adriamycin
11. Involvement of human liver cytochrome P450 3A in vinblastine metabolism: Drug interactions
12. The effects of cyclosporine on the pharmacokinetics of doxorubicin in patients with small cell lung cancer
13. Cyclosporin metabolism in human liver microsomes and its inhibition by other drugs
14. Hepatic biotransformations of docetaxel (Taxotere®) in vitro: Involvement of the CYP3A subfamily in humans
15. The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: Implications for drug interactions
16. Expression of xenobiotic metabolizing enzymes in breast cancer
17. Cytochrome P450 3A-mediated human liver microsomal taxol 6a-hydroxylation
18. Cytochrome P450 expression is a common molecular event in soft tissue sarcomas
19. Xenobiotic metabolizing enzyme expression in colonic neoplasia
20. Expression of xenobiotic-metabolizing enzymes by primary and secondary hepatic tumors in man
21. Tolbutamide 4-hydroxylase activity of human liver microsomes: Effect of inhibitors
22. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes
23. Evaluation of triacetyloleandomycin, a-napthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450
24. Selective inhibition of cytochrome P4502E1 in vivo and in vitro with trans- 1,2-dichloroethylene
25. Tolbutamide as a model drug for the study of enzyme induction and inhibition in the rat
26. Effects of imidazole derivatives on cytochrome P-450 from human hepatocytes in primary culture
27. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme
28. Differential activation of cyclophosphamide and ifosphamide by cytochrome P450 2B and 3A in human liver microsomes
29. Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosphamide
30. O-demethylation of epipodophylloxins is catalyzed by human cytochrome P450 3A4
31. Identification of the cytochrome P450 IIIA family as the enzymes involved in the N-demethylation of Tamoxifen I human liver microsomes
32. Phase I study of etoposide with PSC833 as a modulator of multidrug resistance in patients with cancer
33. The biochemistry of P-glycoprotein mediated multidrug resistance
34. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells